Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about MATINAS BIOPHARMA HOLDINGS, INC.
01/18Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, ..
AQ
2021Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to ..
MT
2021MATINAS BIOPHARMA : Announces Unanimous DSMB Approval to Progress into Fourth and Final Co..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final C..
GL
2021Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final C..
CI
2021Matinas BioPharma Holdings Names Chief Business Officer
MT
2021MATINAS BIOPHARMA : Appoints Thomas Hoover, M.B.A. as Chief Business Officer - Form 8-K
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
2021Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
GL
2021Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
CI
2021Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Confer..
AQ
2021Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
PU
2021Note 2 - Liquidity and Plan of Operations
AQ
2021Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nin..
CI
2021Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
AQ
2021Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial an..
GL
2021MATINAS BIOPHARMA HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
2021Matinas BioPharma Holdings, Inc. Elects Kathryn Corzo to the Board of Directors
CI
2021MATINAS BIOPHARMA : Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best ..
AQ
2021MATINAS BIOPHARMA : Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
MT
2021Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
GL
2021MATINAS BIOPHARMA : Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycosi..
GL
2021Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
CI
2021MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
2021MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
AQ
2021Matinas Biopharma Holdings, Inc. Announces Resignation of Patrick Le Pore as Director
CI
2021Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Inves..
GL
2021MATINAS BIOPHARMA : Says MAT2203 Exceeds Primary Endpoint Threshold of Fungal Clearance in..
MT
2021MATINAS BIOPHARMA : Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Am..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral A..
GL
2021Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the..
CI
2021MATINAS BIOPHARMA : Secures US Patent on MAT2203 to Treat or Prevent Cryptococcus Infectio..
MT
2021MATINAS BIOPHARMA : Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Preve..
AQ
2021MATINAS BIOPHARMA : Positive recent FDA feedback on MAT2501 (oral amikacin) development pr..
PU
2021MATINAS BIOPHARMA : Note 2 - Liquidity and Plan of Operations
AQ
2021MATINAS BIOPHARMA : Reports Second Quarter 2021 Financial Results and Operational Highligh..
AQ
2021Matinas Biopharma Holdings, Inc. Reports Earnings Results for the Second Quarter Ended ..
CI
2021Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
GL
2021MATINAS BIOPHARMA : to Webcast Conference Call Discussing Second Quarter 2021 Financial an..
AQ
2021Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
GL
2021MATINAS BIOPHARMA : MAT2501 (oral amikacin) advanced into preclinical toxicology and effic..
PU
2021MATINAS BIOPHARMA : Piper Sandler Cuts Matinas BioPharma Holdings to Neutral From Overweig..
MT
2021MATINAS BIOPHARMA : Note 2 - Liquidity and Plan of Operations
AQ
2021Matinas Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
2021Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highligh..
GL
2021Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
GL
2021MATINAS BIOPHARMA : to Webcast Conference Call Discussing First Quarter 2021 Financial and..
AQ
2021Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial an..
GL
2021MATINAS BIOPHARMA : Investor Presentation
PU
2021Matinas BioPharma to Present at the Needham Healthcare Conference
GL
2021MATINAS BIOPHARMA : HC Wainwright Adjusts Price Target on Matinas BioPharma Holdings to $3..
MT
2021Matinas Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended ..
CI
2021MATINAS BIOPHARMA : Management's Discussion And Analysis Of Financial Condition And Result..
AQ
2021Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Opera..
GL
2021MATINAS BIOPHARMA : to Webcast Conference Call Discussing Fourth Quarter and Full Year 202..
AQ
2021Matinas BioPharma to Present at the Barclays Global Healthcare Conference
GL
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021MATINAS BIOPHARMA : Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Agai..
AQ
2021Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISOÖ Against V..
CI
2021MATINAS BIOPHARMA HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
2021Matinas BioPharma to Present at the ICR Conference 2021
GL
2021MATINAS BIOPHARMA : Announces FDA Conditional Acceptance of LYPDISO as the Brand Name for ..
AQ
2021MATINAS BIOPHARMA : Receives Conditional FDA OK of Lypdiso as Brand Name for MAT9001
MT
2021Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand N..
GL
2021Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISOÖ as th..
CI
2020MATINAS BIOPHARMA HOLDINGS, INC. : Other Events (form 8-K)
AQ
2020MATINAS BIOPHARMA : Investor Presentat
PU
2020MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2020MATINAS BIOPHARMA : Working With NIAID to Test Oral Formulations of Gilead's Remdesivir; S..
MT
2020MATINAS BIOPHARMA : to Collaborate With NIAID to Test Remdesivir
DJ
2020Matinas BioPharma Announces Collaboration with the National Institute of Allergy and In..
GL
1  2  3  4Next
Upcoming event on MATINAS BIOPHARMA HOLDINGS, INC.
03/30/22